Cytomegalovirus-specific T-lymphocyte therapy (Instituto de Investigación Marqués de Valdecilla)

N/A

Report date: 2022/11/20 22:31:36

Base Information

Drug NameCytomegalovirus-specific T-lymphocyte therapy (Instituto de Investigación Marqués de Valdecilla)
Drug Alias Name巨细胞病毒特异性T淋巴细胞疗法-Instituto de Investigación Marqués de ValdecillaCMV-CTLsCytomegalovirus specific T lymphocytes
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCytomegalovirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInstituto De Investigación Marqués De Valdecilla
China Registration ClassN/A

Develop Information

Active CompaniesInstituto De Investigación Marqués De Valdecilla
Inactive CompaniesN/A
Active IndicationsCytomegalovirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A